Expedeon Inc.
11211 Sorrento Valley Road
Suite C
San Diego
California
92121
United States
Tel: 844-611-3656
Fax: 858-457-7939
Website: http://www.expedeon.com/
Email: info@expedeon.com
About Expedeon Inc.
SYGNIS and Expedeon share a vision of innovation and service by providing cutting edge, patented genomics and proteomics tools to the scientific community. By joining SYGNIS's genomic R&D expertise with Expedeon's proteomic tools and consumables Expedeon will be able to offer a wide variety of innovative products across workflows covering single cell genomics, large scale proteomics and everything in between.YEAR FOUNDED:
January 2008
FOLLOW EXPEDEON:
Tweets by Expedeon
29 articles about Expedeon Inc.
-
4basebio AG announces allotment ratio and final number of shares for the share buy back
2/21/2020
4basebio AG announces the allotment ratio and the final number of shares for the announced share buyback program.
-
4basebio AG decides to buy back 2 million treasury shares
1/21/2020
Voluntary public share buyback offer against cash payment in a purchase price range of EUR 1.60 to EUR 1.85 per share
-
Abcam Announces Successful Acquisition of Expedeon's Proteomics and Immunology Business, Enhancing Its Conjugation Capability
1/6/2020
Includes leading protein conjugation technologies and industry brands Lightning-Link® and CaptSure™
-
Expedeon AG and Abcam plc close EUR 120 million transaction
1/2/2020
Expedeon AG announced the closing of the sale and purchase agreement with Abcam plc, Cambridge, UK, for the sale of the Company’s proteomics and immunology business, as announced on November 11, 2019 and as approved by the Extraordinary Shareholder Meeting on December 19, 2019.
-
Expedeon AG information on EUR 120 million deal with Abcam on dedicated transaction website
11/20/2019
Expedeon AG announced that it has made information available on a dedicated website relating to the transaction agreement with Abcam plc, Cambridge, UK.
-
Expedeon AG signs EUR 120 million deal with Abcam for the sale of its immunology and proteomics business
11/11/2019
Expedeon AG announces the signing of an agreement with Abcam plc, Cambridge, UK, to sell its proteomics and immunology business activities for a cash payment of EUR 120 million.
-
BioSpace Global Roundup, Aug. 8
8/8/2019
Biopharma companies from across the globe share business and development updates. -
Expedeon AG signs commercial agreement with Sona Nanotech
8/6/2019
Agreement will address limitations in development of multiplex point-of-care Lateral Flow Assay diagnostic tests
-
Expedeon AG announces Outcome of Annual General Meeting 2019
7/10/2019
Expedeon AG announced that the Annual General Meeting held in Heidelberg yesterday, July 09, 2019, approved all management proposals.
-
BioSpace Global Roundup: June 27
6/27/2019
Biotech and pharma companies from across the globe share pipeline and business updates. -
Expedeon AG introduces Lightning-Link® Metal Labelling Kits to support single cell analysis
6/24/2019
Novel antibody labelling immunoassay technology for multiplex immune profiling addresses one of the fastest growing, billion-dollar life science market sectors
-
Expedeon AG mandates ODDO SEYDLER BANK AG as Designated Sponsor
6/12/2019
ODDO SEYDLER BANK AG will henceforth be the second Designated Sponsor of Expedeon AG’s share, as Expedeon announced.
-
Expedeon AG adds CaptSure DIY ELISA to immunoassay technology product range
5/28/2019
Addressing a billion-dollar market with innovative technologies which remove bottlenecks in research and discovery
-
Expedeon to Present at the Frankfurt Spring Conference
5/14/2019
Expedeon AG today announced that CEO Dr Heikki Lanckriet will deliver a presentation on 15 May 2019 at the German Spring Conference in Frankfurt.
-
Expedeon Reports First Quarter 2019 Financial Results
5/9/2019
Expedeon AG reported results for the first quarter ended March 31, 2019.
-
Expedeon AG adds ELISA-ONE™ next generation cell signalling assay technology to product offering
5/8/2019
Technology developed by Expedeon company TGR BioSciences
-
Expedeon Reports Financial Results for Fiscal Year 2018 – Financial Guidance Met
4/25/2019
Conference call to be held today, 25 April 2019, 3:00pm CET/2:00pm BST
-
Expedeon Announces Supervisory Board Changes
3/14/2019
Expedeon AG announced that Dr. Cristina Garmendia Mendizábal is to step down as chairwoman of the supervisory board effective April 4, 2019.
-
Expedeon AG licenses Lightning-Link® Rapid Biotinylation technology to Cell Guidance Systems in supply agreement
1/8/2019
License allows Cell Guidance Systems to use Lightning-Link® in manufacture of TRIFic™ exome detection immunoassay kits
-
Expedeon AG reports strong third quarter 2018 financial results
11/8/2018
74% increase in revenues to € 9.3 million for the first nine months of 2018 versus same period in 2017